Technical Analysis for TLC - Taiwan Liposome Company, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical TLC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.19% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.19% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.19% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -5.58% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -5.58% | |
| Inside Day | Range Contraction | -5.58% | |
| MACD Bearish Signal Line Cross | Bearish | -3.74% | |
| Overbought Stochastic | Strength | -3.74% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 10 DMA Resistance | 5 days ago | |
| 1.5x Volume Pace | 5 days ago | |
| Down 5% | 5 days ago | |
| Down 3% | 5 days ago | |
| Down 2 % | 5 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/10/2019
Taiwan Liposome Company, Ltd. Description
Taiwan Liposome Company, Ltd., a biopharmaceutical company, engages in the research, development, and commercialization of lipid-based pharmaceutical products. The company offers products in the areas of oncology, ophthalmology, peripheral arterial disease, fungal infection, anesthetic, and arthritis indications. Its products include Lipotecan, an anti-cancer camptothecin drug; Doxisome, a liposomal encapsulated formulation of doxorubicin; TLC178, a liposomal encapsulated formulation of vinorelbine; ProDex, an ophthalmic drug for the treatment of macular edema; ProFlow, an emulsion form of prostaglandin E1; AmBiL, a liposomal encapsulated formulation of amphotericin B; TLC198, a liposomal encapsulated bupivacaine, enabling the sustained release of a constant amount of local anesthetic; and TLC599, a corticosteroid encapsulated in lipid based drug delivery system for the treatment of inflammation caused by arthritis. The company was founded in 1997 and is headquartered in Taipei City, Taiwan.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Pharmaceutical Products Inflammation Pharmacology Ophthalmic Ophthalmology Drug Delivery Lipid Icos Macular Edema Arthritis Bupivacaine Drug Delivery System Corticosteroid Doxorubicin Fungal Infection Local Anesthetic Arbutus Biopharma Liposome Peripheral Arterial Disease Treatment Of Inflammation Amphotericin B
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.65 |
| 52 Week Low | 2.48 |
| Average Volume | 27,511 |
| 200-Day Moving Average | 5.01 |
| 50-Day Moving Average | 4.96 |
| 20-Day Moving Average | 5.55 |
| 10-Day Moving Average | 5.68 |
| Average True Range | 0.27 |
| ADX | 30.3 |
| +DI | 17.53 |
| -DI | 17.76 |
| Chandelier Exit (Long, 3 ATRs ) | 5.06 |
| Chandelier Exit (Short, 3 ATRs ) | 5.46 |
| Upper Bollinger Band | 6.03 |
| Lower Bollinger Band | 5.07 |
| Percent B (%b) | 0.35 |
| BandWidth | 17.42 |
| MACD Line | 0.19 |
| MACD Signal Line | 0.24 |
| MACD Histogram | -0.0584 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.65 | ||||
| Resistance 3 (R3) | 5.65 | 5.58 | 5.61 | ||
| Resistance 2 (R2) | 5.58 | 5.52 | 5.58 | 5.60 | |
| Resistance 1 (R1) | 5.49 | 5.48 | 5.46 | 5.49 | 5.58 |
| Pivot Point | 5.42 | 5.42 | 5.40 | 5.42 | 5.42 |
| Support 1 (S1) | 5.33 | 5.36 | 5.30 | 5.33 | 5.24 |
| Support 2 (S2) | 5.26 | 5.32 | 5.26 | 5.22 | |
| Support 3 (S3) | 5.17 | 5.26 | 5.21 | ||
| Support 4 (S4) | 5.17 |
